Loading...
Sodium–glucose cotransporter (SGLT)-2 inhibitors lower incidence of first hospitalization and mortality for heart failure (HF) in patients with or without type 2 diabetes (NEJM JW Gen Med Jan 1 2021). Sotagliflozin — an SGLT-1 and SGLT-2 inhibitor that is not yet approved by the FDA — was investigated in an industry-funded, randomized trial in which 1222 patients with type 2 diabetes and HF (80% with reduced ejection fraction) and recent hospitalization for HF received either sotagliflozin or placebo. Patients were followed for a median 9 months.
Compared with placebo recipients, sotagliflozin recipients were equally likely to require subsequent rehospitalization (≈40% of each group) but were significantly less likely to require multiple reh…